U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved additional indications for Harvoni® (ledipasvir/sofosbuvir) for use in chronic hepatitis C patients with advanced liver disease. Harvoni in combination with ribavirin (RBV) for 12 weeks was approved for use in chronic hepatitis C virus (HCV) genotype 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for HCV genotype 1-infected patients with decompensated cirrhosis (Child-Pugh B or C), including those who have undergone liver transplantation. Harvoni is now approved for use in a broader range of patient populations, including HCV genotypes 1, 4, 5 and 6, HCV/HIV-1 coinfection, HCV genotype 1 and 4 liver transplant recipients, and genotype 1-infected patients with decompensated cirrhosis.
“Hepatitis C-infected patients who have decompensated cirrhosis and those who have previously received a liver transplant have an urgent need for treatment, but historically their options have been limited,” said Norbert Bischofberger, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer at Gilead. “We are pleased that health care providers now have the information needed to offer these patients an all-oral, 12-week duration therapy with high cure rates and a tolerable side effect profile.”
Decompensated Cirrhosis and Post-Liver Transplantation
The supplemental new drug application (sNDA) approval for genotype 1 or 4 HCV liver transplant recipients without cirrhosis or with compensated cirrhosis, and for genotype 1 HCV patients with decompensated cirrhosis, was supported by data from the Phase 2 SOLAR-1 and SOLAR-2 trials. These open-label studies evaluated 12 and 24 weeks of treatment with Harvoni in combination with RBV in HCV treatment-naïve and treatment-experienced patients with genotype 1 and 4 infection who had undergone liver transplantation and/or who had decompensated liver disease.
Pooled data from SOLAR-1 and SOLAR-2 among genotype 1 HCV patients are summarized in the table below:
HARVONI + RBV 12 weeks
|SVR12 (N=300)a,b||Relapse (N=288)a,b,c|
|Child-Pugh-Turcotte (CPT) B||87% (45/52)||12% (6/51)|
|88% (35/40)||5% (2/37)|
|Metavir score F0-F3||95% (94/99)||3% (3/97)|
|CPT A||98% (55/56)||0% (0/55)|
|CPT B||89% (41/46)||2% (1/42)|
|57% (4/7)||33% (2/6)|
|a.||Five subjects transplanted prior to post-treatment Week 12 with HCV RNA<LLOQ at last measurement prior to transplant were excluded.|
|b.||Two subjects were excluded due to failure to meet the inclusion criteria for any of the treatment groups (i.e., did not have decompensated cirrhosis and had also not received a liver transplant).|
|c.||Twelve subjects were excluded from relapse analysis because they died (N=11) or withdrew consent (N=1) prior to reaching the 12 week post-treatment follow-up visit.|
SVR12 rates among genotype 4 HCV post-transplant patients without cirrhosis or with compensated cirrhosis (n=12) were similar to the reported genotype 1 SVR12 rates; no subjects relapsed. Available data in subjects with genotype 4 HCV who had decompensated cirrhosis (pre- and post-liver transplantation) were insufficient for dosing recommendations.
A total of seven patients in the 12-week treatment arms of SOLAR-1 and SOLAR-2 had fibrosing cholestatic hepatitis (FCH), and all achieved SVR12. FCH is a rare and severe form of recurrent hepatitis that occurs following liver transplantation and is associated with high morbidity and mortality. Previously, there were no approved treatment options for FCH.
Adverse events observed in the two SOLAR studies were consistent with the expected clinical sequelae of liver transplantation and/or decompensated liver disease, or the known safety profile of Harvoni and/or RBV. Among liver transplant and decompensated liver disease patients, 1 percent and 2 percent of patients discontinued Harvoni with RBV due to an adverse event, respectively. The most common adverse reactions (≥10 percent, all grades) observed with treatment with Harvoni in combination with RBV for 12 weeks were asthenia, headache and cough.
Important Safety Information for Harvoni
If Harvoni is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information.
Warnings and Precautions
Risk of Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with Harvoni due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
Risk of Reduced Therapeutic Effect of Harvoni Due to P-gp Inducers: Rifampin and St. John’s wort are not recommended for use with Harvoni as they may significantly decrease ledipasvir and sofosbuvir plasma concentrations.
Related Products Not Recommended: Harvoni is not recommended for use with other products containing sofosbuvir.
Most common (≥10%, all grades) adverse reactions were fatigue, headache and asthenia.
In addition to rifampin and St. John’s wort, coadministration of Harvoni is also not recommended with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, and tipranavir/ritonavir. Such coadministration is expected to decrease the concentration of ledipasvir and sofosbuvir, reducing the therapeutic effect of Harvoni.
Coadministration of Harvoni is not recommended with simeprevir due to increased concentrations of ledipasvir and simeprevir. Coadministration is also not recommended with rosuvastatin or co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate due to increased concentrations of rosuvastatin and tenofovir, respectively.
Consult the full Prescribing Information for Harvoni for more information on potentially significant drug interactions, including clinical comments.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including risks that physicians may not see the benefits of Harvoni for the additional indications. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
U.S. full Prescribing Information for Harvoni is available at www.gilead.com .
Harvoni is a registered trademark of Gilead Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investors)
Cara Miller, 650-522-1616 (Media)
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cognitec Brings Unique Video Investigation Features to Face Recognition Product for Law Enforcement14.12.2017 09:38 | Pressemelding
Cognitec Systems, the face recognition company, has significantly extended the feature set of its FaceVACS-DBScan product. The latest release combines the company’s renowned image database search technology with powerful video inspection tools for a multitude of investigation use cases. FaceVACS-DBScan LE enables fast import of video footage and detailed investigations of the extracted facial images. Agents can find known or unknown persons in multiple videos to quickly narrow down suspect investigations. The investigation can reveal, for example, if a suspect was seen in various locations within a set time window, always with the same group of persons, or in one location too many times during the day. With one click, the investigator can add the facial image seen in a video frame to a local database. If a person is already known, the technology can quickly compare
The Idle Man Signs Extension with Radial to Support International Business Growth14.12.2017 08:00 | Pressemelding
Radial, the leader in omnichannel commerce technology and operations, today announced London-based menswear fashion retailer, The Idle Man, has signed an extension with Radial to support its international growth and expansion plans. The extension follows Radial’s ability to quickly launch fulfilment, international shipping, and customer service solutions on behalf of The Idle Man from its U.K.-based operations center in Manchester, in just three months. Radial’s services have improved overall customer satisfaction as The Idle Man expands its international footprint. Founded in 2014 by Oliver Tezcan, former menswear buying manager at Asos.com, The Idle Man was established to fill the gap left by mainstream retailers for fashionable men’s clothing at affordable prices. Quickly becoming the third largest menswear destination in the U.K., with over 1.5 million unique visits each mon
SES Drives 5G Satellite Demonstration Testbed Initiative with ESA14.12.2017 07:55 | Pressemelding
SES is expanding its efforts to support 5G developments as part of ESA’s ARTES project, SATis5, where it will be enabling demonstrations of satellite-terrestrial integration for 5G networks. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213006286/en/ SES Drives 5G Satellite Demonstration Testbed Initiative with ESA (Photo: Business Wire) The testbed infrastructure will comprise SES's fleet of Geostationary Earth Orbit (GEO) and Medium Earth Orbit (MEO) satellites, which will be integrated with terrestrial networks and state-of-the-art technologies. In addition to providing the space segment, SES's headquarters in Luxembourg will also host a SATis5 testbed node with prototypes of networks for satellite integration, along with other nodes located in Berlin and Erlangen, and an additional portable no
Alibaba Cloud Becomes the First Cloud Computing Company to Obtain C5 Attestation with Additional Requirements14.12.2017 07:00 | Pressemelding
Alibaba Cloud, the cloud computing arm of the Alibaba Group, announced today that it had completed its assessment for the Cloud Computing Compliance Controls Catalogue (C5) set out by the Federal Office for Information Security in Germany, also known as Bundesamt für Sicherheit in der Informationstechnik (BSI). Alibaba Cloud is the world’s first cloud provider to achieve this attestation with the additional requirements. The attestation covers Elastic Compute Service (“ECS”), Relational Database Service (“RDS”), Object Storage Service (“OSS”), Content Delivery Network (“CDN”), Server Load Balancer (“SLB”), Virtual Private Cloud (“VPC”) and Alibaba Cloud Security available on Alibaba Cloud’s regions in Singapore and Germany. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213006271/en/ Alibaba Cloud becomes t
Alps Electric to Exhibit at Major Chinese Trade Show ELEXCON 201714.12.2017 06:00 | Pressemelding
Japanese electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (President: Toshihiro Kuriyama; Head Office: Tokyo) will exhibit at ELEXCON 2017, to be held at the Shenzhen Convention & Exhibition Center in Shenzhen, China, from December 21. The company will introduce a wide range of technologies, particularly in the Internet of Things (IoT) domain. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213005033/en/ Alps Electric Booth Design (Graphic: Business Wire) At ELEXCON 2017, one of China’s largest electronics expositions, Alps Electric will showcase technologies and solutions targeting each of the Internet of Things (IoT), Mobile and Automotive markets. Exhibit Highlight: IoT Sensor Network Module A sensor module for collecting a variety of data,
Photo Press Release: Giant Gingerbread Burj Khalifa Unveiled at DXB14.12.2017 05:57 | Pressemelding
A 14 metre tall Burj Khalifa made of gingerbread takes centre stage at Dubai Airports’ Winter Wonderland DXB now open at Dubai International’s Terminal 3, B gates. “ Winter Wonderland DXB is the perfect way to get in the festive spirit just moments before jumping on a plane. An instagrammable village scene, set right in the middle of the airport, with entertainment for children and adults, visits from the main man in red on his sleigh and more!” said Helen Mellor-Mitchell, VP Media and Brand Engagement, Dubai Airports. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171213006275/en/ Winter Wonderland DXB arrives at Dubai International Airport (Photo: AETOSWire) Editors Notes Dubai Airports manages the operation and development of both of
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom